Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1608 in Recurrent HSV-2 Genital Herpes
NCT06033261Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Sep 2023
- Primary completion
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of mRNA-1608 in genital herpes, sponsored by Moderna Inc. Started Sep 2023; status: completed.
02
Drugs
mRNA-1608
03
Conditions
genital herpes
Beyond the preview
Go deeper on NCT06033261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06033261.